SPACs for Yield with Crossing Bridge Advisors Founder David Sherman

by | Feb 23, 2022

The bloom may be off the deSPAC rose. But there’s still plenty of opportunity in discounted pre-deal SPACs—even if they don’t make it to the finish line.

SPACs are off to a bumpy start this year.  A macro now approach bear territory has resulted in fewer deal announcements, while many announced transactions are either (1) failing to make it to the finish line — 6 have failed so far this year — or (2) being downsized. At the same time, deSPAC stock performance has been painful to say the least, as rising redemptions, interest rate concerns, deferred revenue/profitability profiles of many new issues, and now potential war in the Ukraine pressure valuations.


Boardroom Alpha Monthly SPAC Review


Relative to 2021, the bloom may be off the SPAC rose. But our latest conversation suggests there are still ways to generate positive returns in SPAC investing. Boardroom Alpha sat down with David Sherman, Founder and Portfolio Manager at SEC-registered investment adviser CrossingBridge Advisors. Based in Pleasantville, New York, with $2.3 billion AUM (Assets Under Management), CrossingBridge specializes in ultra-short duration, low duration high yield and responsible credit strategies in addition to SPACs.

Among his many portfolio manager hats, Sherman manages the CrossingBridge Pre-Merger SPAC ETF (NASDAQ:SPC). The ETF invests only in pre-merger SPACs at or below par value and will only hold the shares for up to 10 days post-merger.

With the deSPAC market in shambles, Sherman’s ETF offers an alternative approach. SPC aims to capitalize on a short-term trading window– the fixed income nature of pre-merger, discounted SPACs that may get an equity “pop” from a deal announcement. Sherman buys pre-merger SPACs below trust value and holds them to redemption or liquidation—ideally generating a positive yield, similar to a short-term zero-coupon bond trading at a discount. SPC’s goal is to generate positive yields that outpace traditional fixed-income products.

The Big Picture for SPACs

  • Valuations on pre-merger SPACs aren’t as fizzy as they used to be. Despite some notable exceptions– like CF Acquisition Corp. (CFVI), which is planning to merge with streaming platform and Joe Rogan affiliated Rumble; and Trump SPAC Digital World Acquisition Corp. (DWAC), investor enthusiasm on announced deals appears to be near zero. Fewer deal announcements and cooling valuations are the new normal as post-close financing via PIPE or otherwise is harder than ever — especially given the high redemption environment.

DWAC is an Anomaly with Even CFVI Barely Only at $12

Most SPACs with Deals Trade Below NAV

Without DWAC, the average for announced deals would be well under NAV.

SPAC Redemptions Are Killing the Market

  • Redemption rates on the rise. Redemptions (89% for February) have been steadily rising since December 2021 (61%), reflecting reduced confidence in business fundamentals. Redemptions were 7% in February 2021. High redemptions have thwarted deals without PIPEs, such as what we saw earlier this week at Astrea Acquisition Corp. (ASAX), which terminated its merger with HotelPlanner and Reservations.com.
  • DeSPACs are increasingly risky business. As Sherman points out, investing in deSPACs is a “random walk” without deep insight into the fundamentals. Notably, the two funds that partially track deSPACs have posted negative returns this year. Morgan Creek Capital Management Exos SPAC Originated ETF (NYSEARCA:SPXZ) is down 14% year-to-date. The Defiance Next Gen SPAC Derived ETF (NYSEARCA:SPAK) is down 15%. In contrast, the S&P 500 (SPX) is down 7% over the same period.

Recent Analysis

Weekly Boardroom & Executive Moves: May 1, 2026

This week, significant leadership changes occurred across several companies facing financial difficulties. Abbott Laboratories (ABT) and Agilon Health Inc (AGL) appointed new board members and executives amidst high activist risks and declining TSRs. Accuray Inc (ARAY) and ALT5 Sigma Corp (ALTS) also saw key executive departures and appointments as they navigate substantial TSR declines. These shifts highlight the ongoing challenges and strategic redirections needed to stabilize operations and improve shareholder value.

Daily SPAC Update – May 1, 2026

Two SPAC IPOs launched today, raising a total of $500 million. CH4 Natural Solutions Acquisition Corp (MTNE) secured $300 million, while Quantum Leap Acquisition Corp (QLEP) raised $200 million. Today, 2 SPAC IPOs raised $500M, led by CH4 Natural Solutions (MTNE) at $300M. This follows a surge of activity at the end of April.

Daily SPAC Update – April 30, 2026

Today, six SPACs debuted, raising a total of $965 million. General Catalyst Global Resilience Merger Corp (GCGR) led the pack with $350 million, followed by RRE Ventures Acquisition Corp. (RREV) at $250 million. Month-to-date, SPAC IPOs total 16, bringing in $2.65 billion, compared to 11 IPOs last month that raised $1.72 billion.

Daily SPAC Update – April 29, 2026

Collective Acquisition Corp. II (CAII) launched its $220 million IPO today, targeting high-potential sectors like technology and healthcare. In executive moves, Roger Bendelac was appointed CEO of both Drugs Made in America Acquisition Corp (DMAA) and Drugs Made in America Acquisition II Corp (DMII), with Saleem Elmasri as CFO. Meanwhile, General Purpose Acquisition Corp (GPAC) saw a significant decline of 22.9%, closing at $9.96, while Aimei Health Technology Co Ltd (AFJK) gained 2.7% to $46.12.

Daily SPAC Update – April 28, 2026

SPAC IPOs Look Stalled Again as Irenic’s $220M IPO Only Makes it Seven. Miluna Acquisition + CADV.AI Deal. Prophyte Extension Vote to Add 12 More Months.

Subscribe to Boardroom Alpha Newsletters

Subscribe to Boardroom Alpha's research to receive the latest on governance, SPACs, and people.

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.